Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedPublications section updated to indicate items are automatically filled from PubMed. Revision tag updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoval of the government funding lapse notice and related operating-status guidance from the page; study data and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedNon-substantive differences seem to be formatting and layout changes across the page; there are no edits to the study purpose, criteria, interventions, or outcomes. Core details such as the title, NCT number, enrollment, locations, and status remain as before. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedCore content updated to v3.2.0 with a government-operating-status notice and a removal of the previous v3.1.0 marker.SummaryDifference2%

- Check78 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated to v3.0.2 and Back to Top removed; no core content or critical information is affected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.